INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43m ago
HOUSE PTR3m ago
SEC 13F3m ago
ROBINHOOD CHAIN2m ago
Public company

FGENKYNTRA BIO, INC.

CIK 0000921299

EDGAR filingsOpen in network
Disclosed transactions11
Buys / sells2 / 0
Max Insider Score29
Connections3with evidence

FGEN · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
11
WT
Wettig ThaneDirector, CEO
KYNBKYNTRA BIO, INC.
Tax withholding
F$1,787
209 sh
Sep 6, 2026Sep 9, 2026
traded Sep 6, 2026
+3dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    DeLucia DavidChief Financial Officer · Dec 9, 2025
  • ← Insider ofevidence
    Wettig ThaneDirector, CEO · Nov 17, 2025
15
DD
DeLucia DavidChief Financial Officer
KYNBKYNTRA BIO, INC.
Tax withholding
F
$188
22 sh
Sep 6, 2026
Sep 9, 2026
traded Sep 6, 2026
+3d
SEC FORM 4

Evidence

5
WT
Wettig ThaneDirector, CEO
KYNBKYNTRA BIO, INC.
Tax withholding
F$1,329
198 sh
Jun 6, 2026Jun 9, 2026
traded Jun 6, 2026
+3dSEC FORM 4

Evidence

9
DD
DeLucia DavidChief Financial Officer
KYNBKYNTRA BIO, INC.
Tax withholding
F$349
52 sh
Jun 6, 2026Jun 9, 2026
traded Jun 6, 2026
+3dSEC FORM 4

Evidence

9
DD
DeLucia DavidChief Financial Officer
KYNBKYNTRA BIO, INC.
Tax withholding
F$410
60 sh
Mar 6, 2026Mar 10, 2026
traded Mar 6, 2026
+4dSEC FORM 4

Evidence

9
DD
DeLucia DavidChief Financial Officer
KYNBKYNTRA BIO, INC.
Grant or award
A—
26.0K sh
Feb 3, 2026Feb 5, 2026
traded Feb 3, 2026
+2dSEC FORM 4

Evidence

5
WT
Wettig ThaneDirector, CEO
KYNBKYNTRA BIO, INC.
Grant or award
A—
60.0K sh
Feb 3, 2026Feb 5, 2026
traded Feb 3, 2026
+2dSEC FORM 4

Evidence

9
DD
DeLucia DavidChief Financial Officer
FGENKYNTRA BIO, INC.
Tax withholding
F$438
52 sh
Dec 6, 2025Dec 9, 2025
traded Dec 6, 2025
+3dSEC FORM 4

Evidence

5
WT
Wettig ThaneDirector, CEO
FGENKYNTRA BIO, INC.
Tax withholding
F$2,181
259 sh
Dec 6, 2025Dec 9, 2025
traded Dec 6, 2025
+3dSEC FORM 4

Evidence

29
WT
Wettig ThaneDirector, CEO
FGENKYNTRA BIO, INC.
Open-market purchase
BUY$25K
2,700 sh
Nov 17, 2025Nov 17, 2025
traded Nov 17, 2025
+0dSEC FORM 4

Evidence

29
WT
Wettig ThaneDirector, CEO
FGENKYNTRA BIO, INC.
Open-market purchase
BUY$9,180
1,000 sh
Nov 13, 2025Nov 17, 2025
traded Nov 13, 2025
+4dSEC FORM 4

Evidence

Source error

Price history for FGEN is unavailable.

An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.